The Fujian Provincial Medical Security Bureau has implemented the “Ten Measures to Support the Innovative Development of the Biomedical Industry”, establishing a comprehensive policy framework designed to leverage medical insurance policies as strategic catalysts for high-quality biomedical sector development. The measures, effective immediately from June 26, 2026, introduce groundbreaking reforms across online listing, pricing mechanisms, medical insurance payments, and multi-tiered coverage systems.
Contents
Policy Framework Overview
| Policy Area | Key Provisions | Implementation Timeline |
|---|---|---|
| Online Listing & Procurement | Dynamic application + centralized review; 15 working days for online listing post-acceptance | Immediate |
| Pricing Mechanisms | Self-assessment guidance; premium pricing for highly innovative drugs reflecting R&D investment; price stability periods | Immediate |
| Medical Insurance Payments | Optimized catalog management; exclusion from basic insurance monitoring metrics; special-case reviews | Immediate |
| Multi-tiered Coverage | Integration of commercial health insurance with basic insurance; simultaneous settlement mechanisms | Phased implementation |
Accelerated Market Access Provisions
- Streamlined Listing Process: Innovative pharmaceutical and medical device products eligible for dynamic application with centralized review
- Rapid Time-to-Market: Online listing completion within 15 working days after centralized acceptance
- Green Channel Establishment: Priority processing for innovative projects addressing major disease treatment gaps
- National Alignment: Accelerated harmonization with national medical service pricing project guidelines
- Administrative Efficiency: Reduced bureaucratic barriers through digital-first procurement mechanisms
Innovative Pricing Framework
| Product Category | Pricing Approach | Key Considerations |
|---|---|---|
| Standard New Drugs | Self-assessment guided by authorities | Clinical value, market supply/demand, competition |
| Highly Innovative Drugs | Premium pricing supported | High R&D investment, development risks, significant clinical value |
| All Innovative Products | Price stability periods | Relative price stability maintained over defined timeframe |
| Market Entry Phase | Flexible initial pricing | Recognition of commercialization challenges and investment recovery needs |
Medical Insurance Payment Reforms
- Catalog Management Optimization: Enhanced flexibility in managing insurance drug catalogs
- Commercial Insurance Integration: Innovative drugs in commercial health insurance catalogs receive preferential treatment:
- Excluded from basic medical insurance out-of-pocket rate indicators
- Exempt from VBP winner substitutable product monitoring scope
- Outside DRG/DIP payment constraint mechanisms
- Dual-Channel System Enhancement: Improved management of dual-channel drug distribution and electronic prescription circulation
- Special-Case Payment Support: Appropriate use of innovative medicines eligible for fee-for-service payment through special-case review processes
Multi-Tiered Coverage Innovation
- Insurance Integration: Promotion of customized commercial medical insurance products integrated with basic medical insurance
- Simultaneous Settlement: Exploration of real-time dual settlement mechanisms for basic and commercial insurance
- Financial Burden Reduction: Direct settlement of pharmaceutical and device payments to suppliers to improve cash flow
- Value-Based Assessment: Advancement of real-world comprehensive value assessment research to inform coverage decisions
Strategic Market Implications
| Stakeholder | Opportunity Assessment |
|---|---|
| Biopharmaceutical Companies | Accelerated market access, premium pricing potential, reduced reimbursement barriers |
| Medical Device Manufacturers | Streamlined listing process, enhanced insurance coverage, improved payment terms |
| Healthcare Institutions | Greater prescribing freedom for innovative therapies, reduced administrative burden |
| Patients | Improved access to cutting-edge treatments, reduced out-of-pocket costs through multi-tiered coverage |
| Commercial Insurers | Expanded role in innovation coverage, partnership opportunities with public insurance system |
Competitive Advantage for Fujian
- First-Mover Status: Among most comprehensive provincial innovation support frameworks in China
- Investment Attraction: Enhanced appeal for biomedical R&D investment and manufacturing establishment
- Talent Retention: Improved ecosystem for biomedical professionals and researchers
- Industry Clustering: Potential to establish Fujian as preferred location for innovative biomedical companies
- Policy Leadership: Demonstrates provincial commitment to becoming national model for biomedical innovation support
Implementation Monitoring & Success Metrics
- Listing Efficiency: 15-working-day target compliance rate
- Pricing Outcomes: Premium realization for highly innovative products
- Coverage Expansion: Growth in innovative drug utilization rates
- Financial Impact: Reduction in supplier payment delays and improved cash conversion cycles
- Patient Access: Measurable improvement in time-to-treatment for innovative therapies
Forward‑Looking Statements
This brief contains forward-looking statements regarding policy implementation, market opportunities, and regulatory reforms. Actual outcomes may differ due to risks including implementation execution, stakeholder adoption rates, and evolving regulatory interpretations.-Fineline Info & Tech
